GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Cash Ratio

Faron Pharmaceuticals Oy (LSE:FARN) Cash Ratio : 0.46 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Faron Pharmaceuticals Oy's Cash Ratio for the quarter that ended in Dec. 2023 was 0.46.

Faron Pharmaceuticals Oy has a Cash Ratio of 0.46. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Faron Pharmaceuticals Oy's Cash Ratio or its related term are showing as below:

LSE:FARN' s Cash Ratio Range Over the Past 10 Years
Min: 0.15   Med: 0.83   Max: 5.04
Current: 0.46

During the past 12 years, Faron Pharmaceuticals Oy's highest Cash Ratio was 5.04. The lowest was 0.15. And the median was 0.83.

LSE:FARN's Cash Ratio is ranked worse than
84.01% of 1476 companies
in the Biotechnology industry
Industry Median: 3.025 vs LSE:FARN: 0.46

Faron Pharmaceuticals Oy Cash Ratio Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Cash Ratio Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.16 0.63 0.95 0.67 0.46

Faron Pharmaceuticals Oy Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 1.09 0.67 0.60 0.46

Competitive Comparison of Faron Pharmaceuticals Oy's Cash Ratio

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faron Pharmaceuticals Oy's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's Cash Ratio falls into.



Faron Pharmaceuticals Oy Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Faron Pharmaceuticals Oy's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5.923/12.933
=0.46

Faron Pharmaceuticals Oy's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5.923/12.933
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Faron Pharmaceuticals Oy  (LSE:FARN) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Faron Pharmaceuticals Oy Cash Ratio Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Traded in Other Exchanges
Address
Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines